The story of Sildenafil presents a intricate picture for investors. While the initial launch generated significant profits, the end of its patent opened the avenue to cheaper alternatives, dramatically reducing market share. This creates a specific challenge for firms relying on related blockbuster offerings, suggesting that a blind stake in the se

The legacy of Viagra, and its developer copyright, presents a challenging case study for investors. Originally a blockbuster drug, producing billions in revenue , its intellectual property lapse created a wave of lower-priced alternatives , significantly impacting its dominance. While some businesses may seek to capitalize on related treatments , t